Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
Stopped limited resources
Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
- DRUG: Lopinavir/Ritonavir
- DRUG: Placebo Administration
- OTHER: Questionnaire Administration
Sponsor
OHSU Knight Cancer Institute
Collaborators